
Q-Line Biotech IPO
- Issue price
- ₹343
- Listing price
- ₹452
- +31.78%
- Current price
- ₹488.3
- +42.36%
- Subscribed
- 102.49x
- Issue size
- ₹251 Cr
- Listed on
- 29 May 2026
IPO timeline
- Opens21 MayThu
- Closes25 MayMon
- Allotment26 MayTue
- Refunds27 MayWed
- Demat credit27 MayWed
- Listing29 MayFri
Issue details
- Price band
- ₹326 – ₹343 per share
- Issue size
- ₹251 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- —
- Face value
- ₹10 per share
- Lot size
- 400 shares
- Minimum investment
- ₹1,37,200
- Listing on
- NSE SME
- Exchange code
- QLINE-SM · QLINE
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 400 | ₹1,37,200 |
| Retail (Max) | 1 | 400 | ₹1,37,200 |
| HNI (Min) | 2 | 800 | ₹2,74,400 |
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on Purva Sharegistry (India)- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 26 May 2026
- Refunds initiated
- 27 May 2026
- Shares credited to demat
- 27 May 2026
- Listing
- 29 May 2026
Grey market premium (GMP)
- Current GMP
- ₹108
- +31.00%
- Estimated listing price
- ₹451
- Issue price ₹343
- Highest
- ₹140
- 21 May
- Lowest
- ₹42
- 18 May
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 27 May 2026 | ₹108 | +31.00% | ₹451 |
| 26 May 2026 | ₹99 | +29.00% | ₹442 |
| 25 May 2026 | ₹126 | +37.00% | ₹469 |
| 23 May 2026 | ₹130 | +38.00% | ₹473 |
| 22 May 2026 | ₹120 | +35.00% | ₹463 |
| 21 May 2026 | ₹140 | +41.00% | ₹483 |
| 20 May 2026 | ₹110 | +32.00% | ₹453 |
| 19 May 2026 | ₹69 | +20.00% | ₹412 |
| 18 May 2026 | ₹42 | +12.00% | ₹385 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB123.94x
- NII (HNI)146.33x
- Retail71.44x
- Anchor1x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 11,88,000 | 14,72,37,200 | 123.94x |
| Non-Institutional Investors (NII) | 8,91,600 | 13,04,66,800 | 146.33x |
| Retail Individual Investors (RII) | 20,79,200 | 14,85,32,800 | 71.44x |
| Anchor Investors | 17,81,200 | 17,81,200 | 1x |
| Total | 41,58,800 | 42,62,36,800 | 102.49x |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Q-Line Biotech This IPO | ₹251 Cr | — | — | — | 102.49x | +31.78% |
| Credent Connect N Care SME · listed 20 Aug 2026 | ₹93.9 Cr | 18.68 | 14.13% | 2.88% | 142.38x | +90.00% |
| Pramodini Medicare SME · listed 19 Aug 2026 | ₹69.04 Cr | 14.97 | 32.69% | 27.90% | 3.66x | +1.69% |
| Bio Medica Laboratories SME · listed 29 May 2026 | ₹52 Cr | 13.45 | 99.59% | 25.64% | 2.31x | -20.00% |
| ABH Healthcare SME · listed 1 Sep 2026 | ₹34.98 Cr | 20.69 | 39.07% | 10.74% | 1.42x | -2.94% |
| Avience Biomedicals SME · listed 25 Jun 2026 | ₹30.24 Cr | 16.56 | 49.89% | 15.86% | 385.4x | +90.00% |
| Speciality Medicines SME · listed 30 Mar 2026 | ₹29 Cr | 10.49 | 28.30% | 14.77% | 2.19x | 0.00% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Q-Line Biotech plans to use the money raised, as stated in the offer document.
About Q-Line Biotech
Q-Line Biotech was incorporated in 2010 and is engaged in the business of developing, manufacturing, and supplying in-vitro diagnostic (IVD) products and medical diagnostic equipment. The company started with a focus on healthcare diagnostics and has gradually expanded its portfolio across clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, ELISA kits, rapid testing kits, and pathology equipment. It operates manufacturing facilities in Delhi and serves hospitals, diagnostic laboratories, and medical colleges across India through a wide distributor network. The company is promoted by Saurabh Garg along with Amita Garg and other promoter group members. Q-Line Biotech follows a business model focused on indigenous manufacturing, imports, distribution, and after-sales support for diagnostic instruments and consumables. The company emphasises affordable healthcare solutions under the “Make in India” initiative while investing in research, quality control, and technology-driven manufacturing to strengthen its position in the Indian diagnostic industry.
Strengths
- Strong presence in the diagnostic and IVD products industry across India.
- Wide product portfolio including biochemistry, molecular diagnostics, ELISA, and rapid test kits.
- Focus on indigenous manufacturing under the “Make in India” initiative.
- Experienced promoter leadership with healthcare industry expertise and nationwide distribution network.
- Strong emphasis on R&D, quality standards, and ISO-certified manufacturing processes.
Risks
- Business depends heavily on the healthcare and diagnostics sector demand cycle.
- High competition from established multinational diagnostic and medical device companies.
- Regulatory changes in medical devices and diagnostic products may impact operations.
- Dependence on continuous innovation and new product approvals for growth.
- Any disruption in raw material supply or distributor network can affect business performance.
Promoters and shareholding
- Shares outstanding, pre-issue
- 96.77
- Shares outstanding, post-issue
- —
Registrar, lead managers and documents
Q-Line Biotech IPO: common questions
1.When does the Q-Line Biotech IPO open and close?
The Q-Line Biotech IPO opens on 21 May 2026 and closes on 25 May 2026.
2.What is the price band of the Q-Line Biotech IPO?
The price band is ₹326 – ₹343 per share, with a lot size of 400 shares and a minimum investment of ₹1,37,200.
3.What is the size of the Q-Line Biotech IPO?
The issue size is ₹251 Cr.
4.What is the GMP of the Q-Line Biotech IPO?
The last reported grey market premium is ₹108 per share as of 27 May 2026, 12:01 PM IST. GMP is unofficial and changes frequently.
5.When is the Q-Line Biotech IPO allotment?
The basis of allotment is expected on 26 May 2026. Allotment status can be checked with the registrar, Purva Sharegistry (India) Private Limited.
6.When will the Q-Line Biotech IPO list?
The shares listed on 29 May 2026 on NSE SME.
7.How can my company launch an IPO like Q-Line Biotech?
Start with an IPO readiness assessment: eligibility for the NSE Emerge or BSE SME platform, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393